Strength of antimicrobial bone cement decreases with increased poragen fraction.

BACKGROUND: Adding soluble particulate poragens to antimicrobial-loaded bone cement increases the permeability of the bone cement and increases the antimicrobial release, but the mechanical effect of adding poragens is not well known. QUESTIONS/PURPOSES: We therefore asked the following questions: (1) Does the poragen fraction in antimicrobial-loaded bone cement affect its antimicrobial release? (2) Does poragen fraction in antimicrobial-loaded bone cement affect its compressive strength; and (3) Does the effect on compressive strength change over time in elution? METHODS: Antimicrobial-loaded bone cement made in the proportions of 40 g polymer powder, 20 mL monomer liquid, 1 g tobramycin powder and one of six different doses of poragen powder (0, 1, 2, 4, 8, or 16 g of particulate xylitol per batch) was formed into standardized test cylinders and eluted for 30 days. We determined the cumulative recovered tobramycin and the change in compressive strength over 30 days of elution. RESULTS: Antimicrobial release progressively increased with increasing poragen fraction. Compressive strength progressively decreased with increasing poragen fraction and with increasing time in elution. Poragen fractions greater than 2 g per batch caused the compressive strength to decrease below 70 MPa over 30 days of elution. CLINICAL RELEVANCE: The use of poragens can increase elution of antimicrobials from antimicrobial-loaded bone cement. However, for implant fixation, to avoid deleterious reduction of compressive strength, the amount of poragen that can be added in addition to 1 g of antimicrobial powder may be limited to 2 g per batch.

Hand-mixed and premixed antibiotic-loaded bone cement have similar homogeneity.

Since low-dose antibiotic-loaded bone cement (ALBC) was approved by the FDA for second-stage reimplantation after infected arthroplasties in 2003, commercially premixed low-dose ALBC has become available in the United States. However, surgeons continue to mix ALBC by hand. We presumed hand-mixed ALBC was not as homogeneous as commercially premixed ALBC. We assessed homogeneity by determining the variation in antibiotic elution by location in a batch, from premixed and hand-mixed formulations of low-dose ALBC. Four hand-mixed methodologies were used: (1) suspension--antibiotic powder in the liquid monomer; (2) no-mix--antibiotic powder added but not mixed with the polymer powder before adding monomer; (3) hand-stirred--antibiotic powder stirred into the polymer powder before the monomer was added; and (4) bowl-mix--antibiotic powder mixed into polymer powder using a commercial mixing bowl before the monomer was added. Antibiotic elution was measured using the Kirby-Bauer bioassay. None of the mixing methods had consistently dissimilar homogeneity of antibiotic distribution from the others. Based upon our data we conclude hand-mixed low-dose ALBC is not less homogeneous than commercially premixed formulations.